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INTRODUCTION
In any radiotherapy treatment, changes in either
the dose-rate or pattern of fractionation will
induce changes in the radiobiological response
of normal tissues and tumours. In mixed
modality regimen an assessment of the overall
biological effect cannot be determined simply by
summing the physical doses instead it is
necessary to make use of the concept of
Biologically Effective Dose (BED) (Barendsen,
1982, Fowler, 1989).
A number of papers have drawn attention to the
potential value of the linear-quadratic (LQ)
model as an aid for solving problems related to
the "iso-effectiveness" of differing radiotherapy
regimen (Dale, 1986; Dale, 1989; Dale, 1990;
Dale, 1990;Fowler, 1989; Matula and Durovec,
1991). However, normal tissue responses are
not governed solely by the pattern of dose
delivery - they depend also on the volume of the
organ irradiated. Furthermore, commonly used
"reference schemes" may not represent the
tolerance dose of a given tissues - they may be
sub-tolerance and therefore provide an
unnecessarily conservative limitation in the
design of an alternative scheme.
The graphical representation of tissue response
suggested by Burman et al (Burman et ai, 1991;
Kutcher et ai, 1991; Lyman and Wolbarst, 1989)
can be used as a quantitative basis for
generating analytical functions with which to
describe the volume effect, al:Jd therefore offer
scope for a more exact evaluation of
radiobiological effects in radiation therapy.
The aim of this contribution is to give:
• a review about the current state using the
Linear-qu~dratic model (LQ) for assessment
biological effects in complex radiation
therapy (brachytherapy + external beam
therapy)
• introduction to the estimating of the NTCP
(normal tissue complications probability
including a volume factor) and the TCP
(tumour control probability)
• presentation of illustrative examples of
simulation .of effects (through .parameters
BED, NTCP and TCP) for rival radiotherapy
treatment protocols.
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RADIOBIOLOGICAL BACKGROUND
The linear quadratic formalism
The linear quadratic formalism was originally
described for the formation of chromosome
aberrations. The application to radiation therapy
has recently been reviewed by Fowler (Fowler,
1989) Dale (Dale, 1986; Dale, 1989; Dale,
1990; Brenner et ai, 1995) and many others.
In this approach the cellular survival, S, at a
dose D is written as
SeD) =exp(-aD- /lD2 ) =exp(-E)
(1 )
Two terms in the exponent (Eq.1) indicate that
the two elementary damaged species may be
produced by the passage of the same tract of
radiation (linear term in dose) or by two different
tracts (quadratic term)
Including of repair to the LQ model
Clearly, if some time elapses between the
passage of the first and second tracts, there
exists the possibility of the first site being
repaired before interacting with the second. The
repair will result in a reduction of the second,
quadratic term in Eq. 1 by a factor denoted the
G'"" .
SeD) =exp(-aD - G/lD2 )
(2)
where a and B are specific parameters of
radiosensitivity (for tumour or normal tissues)
described below. G is a complex tissue specific
parameter and relates to the rate of repair of
1
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sublethal damage under conditions of the
treatment. For more details see (Brenner et ai,
1995; Dale, 1989; Dale, 1990; Dale, 1990).
Including of repopulation to the LQ model
The LQ formalism can take into account the
effects of tumour repopulation (as well as
repopulation in normal tissues) Le. effects on
tumour changes and damages in the overall
time.
( T-t)SeD) = exp -aD - GfJD2 +__0
~ot
(3)
tumors exposed in vivo to two acue doses separed by
the tiem shown on the horizontal axis. Recovery factor
is the ratio of clonogenic survival to that for zero time
separation.
o and lower curve hypoxic tumors exposed to 15 Gy
+ 15 Gy
o and upper curve aerobic tumors exposed to 5 Gy +
5Gy.
The curves are fitted from the LQ model by EqA
For small interfraction times there is a characteristic
rise of recovery factor, attributed to repair of sublethal
lesion; at larger times there is a decrease, attributed
in the model to re-sensitization, the final rise then
being attributed to repopulation.
Including of redistribution and
reoxygenation
The extension of the LQ model to
include the cell cycle redistribution and
reoxygenation has been described by (Brenner
et ai, 1995). In this approach redistribution and
reoxygenation are both regarded as aspects of
a single phenomenon, which has termed as
"resensitization". The general formula of the LQ
model becomes:
( cr T-t)SeD) =exp -aD - GfJD2 +G-D2 +__0
2 ~ot
(4)
T - overall treatment time (days)
to - the delay (days) before which
repopulation or compensatory
repopulation begins.




For specific case of fractionated treatment and
HDR brachytherapy when : T » trepair and
interfraction interval > 6 hours G yields 1 and
(/12 represents a correction less 1% of the
linear term then we can describe the exponent E
in the Eq. 4 into a simple formula:
BED = E =Nd(l+~) -K(t-to)a alfJ
(5)
Fig. 1
Modelling combined effects of repair, resensitization and
repopulation. Data points are from Belli et a!. (2) for P-388 ,
Modelling combined effects of
resensitization and repopulation
explanation is shown on the Figure 1.
Average values of parameters
where:
BED - Biologically Equivalent Dose (in Gy),
RE - Relative effectiveness of a radiation
treatment, N - number of fractions, d - dose per
fraction [Gy], al13 - the parameter of intrinsic,
radiosensitivity for the selected tissue (tumour or
normal tissues) [Gy], K = 0.693/uTpot [Gy/day].
In general, the u/13 ratio (whose unit of measure
is .the gray) has a value found:
3 - 5 Gy for late reacting normal tissues and
10 -30 Gy for tumours and early reacting
normal tissues.
The relative effectiveness (RE) of the treatment
depends on the size of dose per fraction and on
the responding .al13 ratio. The changes of the
effects with size of the dose/fraction and the al13
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The consequences of repopulation
Fig.2
Linear-quadratic dose-response curves for early and late
effects with illustration of definition for the a/~ ratio.
(B) ( 7)
=BEDa/~ (A)
Equalizing schemes using concept of the LQ
model
0.46 - 1.4 h-1 for tumours and early-reacting
tissues (responding to half-times in the range
1.5- 0.5h.
Comment: The Eq. 6 is specific form of more
general equations which are applied to more
complex treatment regimen, ego those involving
short interfraction intervals e.g. PDR
brachytherapy or short intervals between
fractions in HDR and EBRT (Brenner et ai,
1995). For more details see papers (Brenner et
ai, 1995; Dale, 1986; Dale, 1989)
Conclusion
The mechanisms of changes on tumour cell
population and normal tissues, characterized by
well known "four R's" of radiobiology (Repair,
Repopulation, Reoxygenation and
Redistribution) can be now described by the
extended LQ model.
There are still strong requests on experimental
and clinical studies to precise parameters in the
LQ model.
In general two schemes (A) and (B) are iso-
effective in their radiation effects on a selected
























The biological effect on the tumour is likely
greater in fractionated regimen if the treatment
is kept reasonably short (Le. if the treatment is
accelerated).
The effect will also be enhanced if the tumour is
characterised by a high radiosensitivity and/or a
large potential doubling time (Le. if it divides
sloWly)
Values of "K" vary from:
o-0.1 Gy/day for late reacting tissues,
o-0.3 Gy/day for early reacting tissues
o-0.6 Gy/day for tumours
The repopulation is initially slowed up until a
certain time (to) (typically 14 -28 days) after
which it accelerates. RepopUlation for late
reacting tissues can be nearly neglected.
Linear-quadratic formalism for continual
brachytherapy
In low/medium dose-rate (LDRlMDR)
brachytherapy the relevant equation derivated
from Eq. 4 is:
For treatments composed of a number of
individual courses (e.g. EBRT + brachytherapy)
the BED's associated with the individual
components may be summed to give an overall
measure of biological effect.
In order to be unambigueous as to which tissue
effects are being discussed, it is useful to assign
a subscript after the BED in accordance with the
a/f3 value which has been selected for the




R - dose rate in [Gy/h]
T - treatment time [hours]
I..l - repair constant [h-1]
Typical values used for I..l:
0.46 h-1 for late-reacting tissues (responding to a
half-time for repair of 1.5 h)
lJustrative example:
What is the relative effectiveness RE and BED
for daily fractionation 30F/2Gy for tumour and
late reacting tissues in comparison with
hyperfractionation applied with the same total
dose (60 Gy) but in 40 Fr/1.5Gy/both in day.
Calculation:
Using Eq. 5 anda/r!, = 10 Gy for tumour and 3
Gy for late reacting tissues we can get:
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RE10 =1 + 2/10 =1.2 RE10 =1 + 1.5/10 =
RE3 =1 + 2/3 =1.66 1.15
BED10 =72 Gy RE3 =1+ 1.5/3 =1.5
BED3 =99.6 Gy BED10 =69 Gy
BED3 =90 Gy
Conclusion:
Hyperfractionation has a lower effect on
tumours (less at 4%) but an impressive "saving"
effect on late reacting tissues (at 10%) !
However, the higher or lower value of the BED
for late effects does not give an answer how the
percentage will increase or decrease of
complications in comparison with the reference
scheme. This information can be achieved using
concept of the NTCP explained below.
CALCULATION OF NTCP
In this paper they have compiled clinical
tolerance data for 29 normal tissues and fitted it
to sigmoid-type curves in order to represent the
response when daily fractionation is used. The
difference in response between uniform and
partial irradiation is expressed as a function of
the delivered dose and the volume irradiated by
means of Lyman'S 4-component model (Lyman
and Wolbrast, 1989).
There are shown analytic functions representing
complication probabilities vs. dose and volume
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Fig. 3
Fitted curves of complication probabilities NTCP depending
on dose and irradiated volume of tissue for 3 fixed values of
partial volume: 1 - whole volume, 2/3 and 1/3 volume
(reproduced with permission from Burman et al. (4))
Lyman'S model for daily fractionation
The normal tissue complication probability can
be described by the model introduced by J.
Lyman (Lyman and Wolbrast, 1989)




End Point severe proCUlS InecroSisl
Reference Volume: Whole organ
DOSE (Gy)
End Point Symptomatic bladder
contracture and volume loss
Reference VOlume: 'lJl/hole organ
(8)
DlIPp/ - TDso(v)t =--'-'-----
mTDso(v)
where:
v - VN ref
V - partial organ volume irradiated
Vref - whole organ volume,
respectively
TD(v) = TD(1). v·n
(8a)
n - specificorgan volume
parameter
m - specific organ dose parameter
DapPI - total applied dose to ~issue
TDso - dose related to produce 50% of
complication
The parameters n, m, TDs/s, TDso/s for 29 normal
tissues and end points have been chosen from
the paper Burman et a!. (Burman et ai, 1991;
Kutcher et ai, 1991).
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Generalisation of Lyman s model to non-
daily fractionation
The Eq. 8 may be applied for any other (non-
daily fractionation) regimen, when "t" is re-
defined as:
. t = BEDlIPp/ - BEDso(v)
mBEDso(v)
(9)
This generalisation of Lyman s model enables to
estimate predictive values of NTCP in any
treatment modalities and their combinations.




it is possible to determinate ..Effective partial
volume" (from dose volume histogram), and
then, to calculate particular BED and NTCP.
The associated radiobiological parameters
taken from a set of the latest papers {Belli et aI,
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1967; Fowler, 1984; Fowler, 1984; Fowler,
1989; Kutcher et ai, 1991) and calculated BEDs/s
(Le. BED related to NTCP = 5% I 5 years) and
BEDso/s (related to NTCP =50% I 5 years) are
summarized in the Table 1.
Table 1. The radiobiological data of the normal late reacting tissues collected from papers (Trott and Kummermehr, 1985;
Fowler, 1989; Kutcher et ai, 1991) as a data-base to the program.
Normal tissue Clinical end point TDs/s alp Fr. T n m BEDs/s
[Gy] [Gy] days [Gy]
Bladder contracture, loss 65 5 33 45 0.5 0.11 91.0
Brach.Plexus din.nerv.damage 60 5 30 40 0.03 0.12 84.0
Brain stem necrosis,infarct. 50 2.5 25 33 0.16 0.14 90.0
Brain necrosis,infarct 45 2.5 22 30 0.25 0.15 79.2
Cauda equina nerve damage 60 2.5 30 40 0.03 0.12 108.0
Colon pertor. ,fistula 45 5 22 30 0.17 0.11 61.6
Ear-middle chron.ser.otitis 55 5 27 37 0.01 0.09 75.6
EsophaQus pertor.stricture 55 5 27 37 0.06 0.11 75.6
Eye-lens cataract.-interv. 10 1.2 5 5 0.3 0.27 22.7
Eye-opt.nerve blidness 50 1.2 25 33 0.25 0.14 133.3
Eye-retina blidness 45 1.2 22 30 0.20 0.19 117.3
Femoral H N necrosis 52 5 26 36 0.25 0.12 72.8
Heart peri .pancarditis 40 3 20 26 0.35 0.10 66.7
Intestine obstruct.pertorat. 40 5 20 26 0.15 0.16 56.0
Kidney clin.nephritis 23 4.1 11 15 0.70 0.10 32.7
Larynx cartilag.necros. 70 3.8 35 47 0.11 0.07 106.8
Larynx laryng.edema 50 3.8 25 33 0.08 0.17 76.3
Liver failure 30 3 15 19 0.32 0.15 50.0
Lung chron.pneumonitis 17 3.7 9 11 0.87 0.18 27.0
Parotid xerostomia 32 5 16 22 0.70 0.18 44.8
Rectum sev.proct.necros. 60 5 30 40 0.12 0.15 84.0
Rib cage patholJracture 44 5 22 30 0.10 0.21 61.6
Skin necros. ulcerat. 55 3.7 27 37 0.10 0.12 83.3
Spin.cord c. myelitis,necros. 46 2.5 23 31 0.05 0.17 82.8
Spin.cord I. myelitis necros. 46 5.2 23 31 0.05 0.17 63.7
Stomach .pertor.,ulcerat. 50 3 25 33 0.15 0.14 83.3
Thyroid clin.thyroiditis 46 5 23 31 0.22 0.26 64.4
TM ioint limited function 60 5 30 40 0.07 0.10 84.0
Comments: TDs/s - total dose related toNTCP = 5% during 5 years. For all late reacting normal
tissues: J..l =0.46 h-1, K =0.01 Gy/day. Starting of repopulation after 60 days, finishing of repopulation
100 days.
As the calculation using BED, TCP and NTCP
concepts is highly time-consuming, we have
developed a comprehensive computer program
RADBIO which renders many options for flexible
calculation all radiobiological parameters
explained above.
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Using the program there can (in a "user-friendly"
dialogue) be input the treatment and dosimetric
data of applied protocols and to get the results
in the form of a comprehensive radiobiological
report (see Table 2). The application of BED,
NTCP and TCP is demonstrated on several
examples.
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Table 2. The ouput of the program RADBIO - an illustrative example
RADIOBIOLOGICAL PATIENT REPORT
NAME OF PATIENT: XY. by protocol for Ca uter.cervix
Selected tissue: TUMORRESP. LATE EFF. LATE EFF
CERV.CORP. RECTUM BLADDER
Alfa/beta ratio [Gy}: 13.90 5.00 5.00
Repair. half time [Hour]: 0.50 1.51 1.51
Repopul. factor [Gy/Day}: 0.30 0.01 0.01
BED reference [Gy]: 75.54 84.20 89.76
LOG CELL KILL reference: 9.85 10.98 11.70
APPLIED COURSE NAME: EBRT 24F/1.7Gy/day 2AP/PA
Number of fractions: 24 24 24
Dose / fraction [%}: 95.00 90.00 90.00
Dose / fraction [Gy}: 1.70 1.61 1.61
Treatment time [Days]: 33 33 33
Whole dose [Gy}: 40.80 38.64 38.64
Treatment gap [Days]: 10 10 10
BED applied [Gy}: 37.09 51.25 51.25
LOG CelL KILL: 4.84 6.68 6.68
APPLIED COURSE NAME: 4F HDR 6Gy/AJ2F/week
Number of fractions: 4 4 4
Dose / fraction [%}: 100.00 75.00 80.00
Dose / fraction [Gy]: 6.00 4.50 4.80
Treatment time [Days}: 11 11 11
Whole dose [Gy}: 24.00 18.00 19.20
Treatment gap [Days]: 0 0 0
BED applied [Gy}: 31.06 34.26 37.69
LOG CELL KILL: 4.05 4.47 4.92
COMPARISON OF SCHEMES
BED reference [Gy}: 75.54 84.20 89.76
LOG CELL KILL reference: 9.85 10.98 11.70
BED applied [Gy]: 68.15 85.51 88.94
LOG CELL KILL applied: 8.89 11.15 11.60
BED residual [Gy]: 7.39 -1.31 0.82
LOG CELL KILL residual: 0.96 -0.17 0.11
TOTAL DOSE [Gy]: 64.80 56.64 57.84
TOTAL TIME [Days]: 54.00 54.00 54.00
DE F: *0.90 1.02 0.99
Volume: TCP NTCP(R) NTCP(B)
10 %: 0% 0% 0%
20% : 0% 0% 0%
30%: 0% 1% 0%
40% : 1% 2% 0%
50% : 23% 3% 0%
60% : 56% 3% 0%
70% : 76% * 4% * 0%
80% : 87% 5% 0%
90% : 93% 5% 1 %
100% : * 96% 6% 4%
Conclusion: Individual radiobiological report for a patient after treatment by the protocol (24F/1.7Gy +
4 HDR 6Gy/point A). Critical rectal and bladder dose are averaged to 75 and 80 % related to the point
h.. DEF = 0.90, TCP = 96%, NTCPRectum = 4 % NTCP Bladder = 0 %.
Application and results
A well-known protocol Phase III randomised
comparison of 5 FU/CACP vs. HU as
potentiators of radiotherapy in patients with
stages liB, III and IV-A Ca of the cervix with
6
negative para-artie nodes (ID:GOD-85) has
assumed application of radiation therapy:
• EBRT: 24 fraction I 1.7 Gyl day - AP
IPA open fields
Rep. Pract. Oncol. 2 (1) 1997
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• CLOR: 2 insertions / 20 Gy / "point A",
gap 1-3 weeks
From the technical reasons the previous CLOR
treatment has been neccessary to substitute by
HOR brachytherapy treatment. The physician
has proposed to apply 4 fractions with 6
Gy/"point A". External beam therapy on whole
pelvis remained the same.
There is a question on place: What is an
equivalent dose on HOR fraction versus LOR
regime for the tumour and critical organs
(bladder and rectum)?
Solution: .
Entries of treatment parameters of previous
LOR + EBRT (as a "users scheme") are
compared with proposal HOR scheme.
CERVIX II-B. III. (40.8 Gy/24F/1.7 Gy + 2F LOR!20 Gy
TCP. NTCP, SF = TCP (1 - NTCP) [%]
From 30-brachytherapy isodose plans we have
taken maximal critical rectal and bladder
percentage doses as needed input parameters
to the program. The output of the program
RAOBIO for one specific case of dosimetric data
and treatment protocol is shown at the Table 2.
To achieve a complex picture on relationships
tumour response, late effects depending on
dosimetric and treatment parameters the
program renders these relations in graphical
presentation where percentage doses on
selected tissues (tumour, rectum and bladder)
are variables and EBRT is applied as a fixed
standard.
The results of this simulation for both protocols
are shown on the Figure 4 and Figure 5.
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Therapeutic ratio for sensib. Protocol cervix II-B, III, (40.8
Gy/24F/1.7 Gy +F LDR/20 Gy)
NORMALIZED TO 100% /point A
CERVIX II-B, III, (40.8 Gy/24F/1. 7 Gy +4F HDR 6.5 Gy/A)
TCP, NTCP, BF = TCP (1 - NTCP) [%]
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Fig, 5
Therapeutic ratio for sensib. Protocol cervix II-B, III, (40.8
Gy/2F/1.7 Gy + 4F HDR 6.5 Gy/A)
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Table 3. Critical % dose refered for isoefective
regimen LDR vs. HDR
The "Therapeutic Ratio" we evaluated using so
called "Benefit function" defined as:
SF =TCP (1 - NTCP)
The maximum of SF can be taken as one of the
measures of the "optimal therapeutic gain" of
tumour response vs. selected tissue
dose tolerance. Conclusion of simulation are
summarized in Table 3.
Critical % dose refered to NTCP
=5%
Regime
2Fr LOR + EBRT







and more detailed geometric and dosimetric
information about specific HDRapplications can
be used as a good basis for comparing actual
and theoretically predicted NTCP's. DVH
software is available in most advanced
computer systems and may be used to provide
data which can be used in more advanced
radiobiological calculations, such as those
available in the RADBIO program (Matula and
Durovec, 1991). The program database is easily
accessible in order to allow for any revisions in
the values of radiobiological parameters which
may emerge from future experimental and
clinical analyses. It is expected that, as more
reliable tolerance data becomes available, the
estimated NTCP's will more closely match those
determined clinically. When the data base of all
radiobiological parameters is a part of the
program,the entry of treatment data is simple
and takes only 1 - 2 minutes of the clinicians
time.
Comment:
Obviously, any changes in the EBRT are likely
to have a consequential influence on the shapes
and values of the critical isodoses on the rectum
and the bladder.
DISCUSSION
The important point which emerges from this
contribution is the strong dependence of the
NTCP of particular tissues on the HDR
percentage dose which they receive. Increasing
the HDR percentage dose to the rectum from
70% to 80% increases the NTCP by a factor of
three. Similarly, increasing the HDR percentage
dose to the bladder from 85% to 95% gives a
four-fold increase in NTCP.
The careful dosimetric study at Manchester,
based on CT localization of the bladder,
revealed that the percentage dose to 'this organ
ranged from between 53 and 143%. Similarly,
percentage dose to the rectum ranged from
between 30 - 100% (Hunter et ai, 1986).
The initial attempts in applying of a small
number of HDR fractions (and insufficient
attention devoted to dosimetric and
radiobiological consequences of these high
dose fractions on the normal tissues along with
the tumour) have followed to unfavourable rates
of late complications. There unfavourable
results in HDR brachytherapy evoked scruples
(doubts) about a convenience of HDR
brachytherapy. These have been dispersed by
the next studies and more detail dosimetric
calculations and radiobiological modelling.
The availability of sophisticated 3-D software
and optimized calculation software ought to
allow a reduction in variances such as these,
8
GENERAL CONCLUSION
In spite of the cautions and reservations relating
to the applications of radiobiological models in
the evaluation of treatment protocols and their
correlation with clinical results, the concepts of
BED and NTCP have their greatest impact in the
following areas:
• in the initial design of new treatment
schemes to match (or improve) the results of an
already established protocol.
• in identifying the nature of the radiobiological
parameters which have greatest influence on
the treatment outcome and which need to be
further investigated.
• in eliminating the imperfections of
established schemes
• in providing new perspectives into the
evaluation of different "rival" treatment protocols.
ACKNOWLEDGMENTS:
I have pleasure in thanking for particular
encouragment contributed by Profs. R.
Gahbauer and S. Nag during the study stay of
the author on Department of Radiation
Oncology, OSU, Columbus, USA. The work was
supported in part by UICC ICRETT fellowship (a
grant No.512/1992) and to Dr. R.G. Dale from
Dept. of Medical Physics. Charing Cross
Hospital, London and Dr J. Koncik.
Rep. Pract. Oncol. 2 (1) 1997
Matula: How effectively to use biophysical models in treatment planning?
REFERENCES
Barendsen, G. W. Dose fractionation, dose rate and
isoeffect relationships for normal tissue response. Int.
J. Radial. Oncol. BioI. Phys.8: 1981-1997, 1982.
Belli, JA, Dicus G.J., Bonte F.J.: Radiation response
of mammalian tumor cells I.Repair of sublethal damge
in vivo J. Natl. Cancer Inst. 38:673-682,1967
Burman,C., Kutcher,G., Emami,B., Goitein,M.: Fitting
of normal tissue tolerance data to an analytic function.
lnt. J. Radiat. Oncol. BioI. Phys. 21 :123/135;1991
Brenner D.J., Hlatky L.R., Hahnfeldt P.J., Hal! E.J.:
Convenient extension of the linear-quadratic model to
include redistribution and reoxygenation Int. J. Rad.
One. BioI. Phys., Vo1.32, No 2,379-90,1995
Dale, R G.: The application of the linear-quadratic
model to fractionated radiotherapy when there is
incomplete normal tissue recovery between fractions,
and possible implications for treatments involving
multiple fractions per day. Br. J. Radiol. 59: 919-927,
1986.
Dale, R G.: Time-dependent tumour repopulation
factors in linear-quadratic equations-implications for
treatment strategies. Radiother. Oncol. 15:371-382,
1989.
Dale, RG.: The potential for radiobiological modelling
in radiotherapy treatment design Radiotherapy and
Oncology, 19, (1990) 245-255
Dale R.G.: The use of small fraction numbers in HDR
gynecological afterloading: some radiobiological
considerations Brit. J. of Radiol. 63,1990, 290-294
Fowler,J.F.: What next in fractionated radiotherapy?
Br. J. Cancer 49: Suppl.VI, 285-300,1984.
Fowler, J. F.: Review article: The linear-quadratic
formula and progress in fractionated radiotherapy. Br.
J. radial. 62, 679-694, 1989.
Hunter R, Wang S.: Bladder base dosis in patients
undergoing intracavitary therapy. Radiotherapy and
Oncology 7,189-197,1986.
Rep. Pract. Oneal. 2 (1), 1997
Kutcher,G.J.; Burman,C.; Brewster,L.; Goitein, M.;
Mohan,R.: Histogram reduction method for calculating
complication probabilities for three-dimensional
treatment planning evaluations. Int. J. Radial. Oncol.
BioI. Phys. 21:137-146,1991
Lyman, J.T.; Wolbarst, A.B.: Optimization of radiation
therapy, IV.A Dose-volume histograms reduction
algorithm Int. J. Radial. Oncol. BioI. Phys. 17:433-
436; 1989
Matula,P.; Durovec,K.; New aspects in radiobiological
evaluation of intracavitary dose rate effects in mixed
treatments. Proceedings Sixth International HDR
Remote Afterloading Conference: 11-17,1991
Matula, P. Dale, RG. Durovec, K., Radiobiological
evaluation of intracavitary dose rate effects in
combined external beam and intracavitary treatments.
Selectron Brachytherapy J., Activity Vol. 4, No.2,
1990.
Niemierko,A.,Goitein,M.: Calculation of normal tissue
complication probability and dose-volume histogram
reduction schemes for tissue with a critical element
architecture. Radiother. Oncol. 20:166-176,1991.
Shigematsu, Y., Nishiyama, K., Masaki, N., Inoue, T.,
Miyata, Y., Ikeda, H., Ozeki, S., Kawamura, Y.,
Kurachi, K.: Treatment of carcinoma of the uterine
cervix by remotely afterloading intracavitary
radiotherapy With high-dose: A comparative study with
a low-dose rate system. lnt. J. Radiat. Oncol. BioI.
Phys. 9:351-356,1983
Thames, H.D., Bentzen, S.M., Turesson, I.,
Overgaard, M., Van den Bogaert, W.: Time-dose
factors in radiotherapy: a review of the human data
Radiother. Oncol. 19:219-235,1990
Trott, K.R, Kummermehr, J.: What is known about
tumour proliferation rates to choose between
accelerated fractionation or hyperfractionation?
Radiother. Oncol. 3:1-9,1985.
9
